Compare AIXC & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIXC | LSTA |
|---|---|---|
| Founded | 1996 | 1980 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 28.9M |
| IPO Year | N/A | 2000 |
| Metric | AIXC | LSTA |
|---|---|---|
| Price | $0.79 | $1.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 35.6K | ★ 65.8K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.68 | $1.81 |
| 52 Week High | $2.98 | $5.07 |
| Indicator | AIXC | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 19.52 |
| Support Level | N/A | N/A |
| Resistance Level | $1.45 | $2.19 |
| Average True Range (ATR) | 0.11 | 0.22 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 35.42 | 1.40 |
AIxCrypto Holdings Inc is a technology infrastructure company focused on the convergence of artificial intelligence and blockchain-based programmable systems. The Company develops software platforms and programmable infrastructure designed to facilitate the tokenization of real-world assets (RWA) and the deployment of Embodied Artificial Intelligence (EAI) in commercial environments. Its mission is to serve as the regulated, programmable infrastructure layer connecting traditional capital markets with on-chain systems and AI-enabled commercial systems.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.